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Abstract
Background: Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS)
and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and
efficacy of arbaclofen for social avoidance in FXS.
Methods: Two phase 3 placebo-controlled trials were conducted, a flexible dose trial in subjects age 12–50
(209FX301, adolescent/adult study) and a fixed dose trial in subjects age 5–11 (209FX302, child study). The
primary endpoint for both trials was the Social Avoidance subscale of the Aberrant Behavior Checklist-Community
Edition, FXS-specific (ABC-CFX). Secondary outcomes included other ABC-CFX subscale scores, Clinical Global
Impression-Improvement (CGI-I), Clinical Global Impression-Severity (CGI-S), and Vineland Adaptive Behavior
Scales, Second Edition (Vineland-II) Socialization domain score.
Results: A total 119 of 125 randomized subjects completed the adolescent/adult study (n= 57 arbaclofen, 62 placebo)
and 159/172 completed the child study (arbaclofen 5 BID n= 38; 10 BID n= 39; 10 TID n= 38; placebo n= 44). There were
no serious adverse events (AEs); the most common AEs included somatic (headache, vomiting, nausea), neurobehavioral
(irritability/agitation, anxiety, hyperactivity), decreased appetite, and infectious conditions, many of which were
also common on placebo. In the combined studies, there were 13 discontinuations (n = 12 arbaclofen, 1 placebo)
due to AEs (all neurobehavioral). The adolescent/adult study did not show benefit for arbaclofen over placebo for
any measure. In the child study, the highest dose group showed benefit over placebo on the ABC-CFX Irritability
subscale (p = 0.03) and Parenting Stress Index (PSI, p = 0.03) and trends toward benefit on the ABC-CFX Social
Avoidance and Hyperactivity subscales (both p < 0.1) and CGI-I (p = 0.119). Effect size in the highest dose group
was similar to effect sizes for FDA-approved serotonin reuptake inhibitors (SSRIs).
Conclusions: Arbaclofen did not meet the primary outcome of improved social avoidance in FXS in either study.
Data from secondary measures in the child study suggests younger patients may derive benefit, but additional
studies with a larger cohort on higher doses would be required to confirm this finding. The reported studies
illustrate the challenges but represent a significant step forward in translating targeted treatments from preclinical
models to clinical trials in humans with FXS.
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Background
Fragile X syndrome (FXS) is an X-linked condition that,
with a prevalence estimated at 1 in 4000 males and 1 in
8000 females [1], is the most common known inherited
cause of intellectual disability and the most common
single gene cause of autism spectrum disorder (ASD).
FXS is associated with characteristic behavioral features
such as attention deficits, hyperactivity, anxiety, mood
lability, and in some cases aggression, as well as autistic
features including prominent perseverative behavior and
social impairments [2]. At present, no symptomatic or
disease-modifying treatments for FXS have received
regulatory approval.
FXS is typically caused by an expansion (>200) of a
CGG trinucleotide repeat sequence in the promoter
region of the Fragile X Mental Retardation 1 (FMR1)
gene. This expansion is associated with complete or
partial methylation of the FMR1 promoter, resulting in
loss or significant reduction of expression of the gene
product, FMRP (fragile X mental retardation protein)
[3]. Females with FXS tend to be less severely affected
than males due to expression of the normal X chromo-
some [4]. FMRP is an RNA-binding protein that modu-
lates the dendritic localization and translation of several
hundred mRNA ligands [5]. In the Fmr1 knockout mouse,
the absence of FMRP leads to excessive protein synthesis
downstream of signaling pathways coupled to group I
metabotropic glutamate receptors (mGluRs), in particular
mGluR5. Inhibition of mGluR5 and downstream signaling
has been shown to correct a wide array of disease pheno-
types in animal models of FXS [6].
Glutamatergic transmission is under tight regulation
by GABAergic inhibition, and deficiencies in γ-amino-
butyric acid (GABA-mediated inhibitory neurotransmission
have been identified in the hippocampus, striatum, somato-
sensory cortex, and amygdala of Fmr1 knockout mice [7].
Use of GABA agonists has been suggested as a therapeutic
strategy for FXS [8]. In fact, preclinical animal data showed
rescue of glutamate-induced lethality, neuropathology,
excessive protein translation, and abnormal courtship
behavior in the dfmr mutant fly with GABAergic com-
pounds [9]. In Fmr1 knockout mice, studies have shown
improvement in elevated plus maze performance with the
GABA-A agonist alphaxalone, and protection from audio-
genic seizures with the GABA-A agonist ganaxolone and
the racemic GABA-B agonist baclofen [10]. In addition to
ameliorating audiogenic seizures, treatment of Fmr1 knock-
out mice with the (R)-(+)-enantiomer of baclofen corrects
some core features of FXS pathophysiology, including
excessive basal protein synthesis, increased activity of
the mammalian target of rapamycin pathway, and
abnormal spine density [11, 12].
Arbaclofen (STX209, R-baclofen) is a potent and
selective agonist of GABA-B receptors and contrasts
with (S)-(-)-baclofen with respect to metabolism, CNS
transport, and activity [11]. In humans, arbaclofen shows
pharmacokinetic properties similar to those of racemic bac-
lofen, with high bioavailability and a terminal half-life of 4
to 5 h. Arbaclofen undergoes renal elimination with no
significant metabolism [13]. Based on preclinical work,
anecdotal clinical experience suggesting behavioral benefits
from racemic baclofen in FXS and autism spectrum
disorder (ASD), and data from transcranial magnetic
stimulation (TMS) studies demonstrating enhancement of
cortical inhibition by racemic baclofen [14], a phase 2
double-blind placebo-controlled flexible dose crossover trial
of arbaclofen was conducted in (n = 63) subjects with FXS
[15]. All subjects met severity criteria on the Aberrant
Behavior Checklist-Community Edition (ABC-C) Irritability
subscale, which was the primary endpoint based on FDA
precedent for use of this scale for prior approval of risperi-
done and aripiprazole for irritability in ASD.
In that trial, arbaclofen showed no significant safety
issues. Although there was no benefit for arbaclofen
over placebo on the primary outcome, significant im-
provement over placebo was seen on a visual analog
scale (VAS) for the three most severe parent-nominated
behaviors and on the ABC-CFX (ABC-C refactored for
FXS population [16]) Social Avoidance subscale, with a
trend in favor of arbaclofen also for blinded treatment
preference as reported by clinicians and parents, the
Clinical Global Impression-Severity (CGI-S), and Clinical
Global Impression-Improvement (CGI-I). In a post hoc
analysis, arbaclofen showed significant improvement over
placebo in the more socially impaired subgroup (n = 27)
for the treatment period preference (both clinician and
parent), CGI-I, CGI-S, Vineland Adaptive Behavior
Scales, Second Edition (Vineland-II) Socialization domain,
ABC-C Lethargy/Social Withdrawal subscale, ABC-CFX
Social Avoidance subscale, and a responder analysis (CGI-I
of much or very much improved and at least 25% improve-
ment on ABC-C Lethargy/Social Withdrawal). The results
were also more robust among subjects who met Diagnostic
and Statistical Manual of Mental Disorders-Fourth Edition
(DSM-IV) and Autism Diagnostic Interview-Revised
(ADI-R) criteria for autistic disorder. Significantly more
subjects were responders on the CGI-I scale when re-
ceiving arbaclofen vs. placebo (35 vs 18% overall; 50 vs.
6% autism) in the autism subgroup, although again the
ABC-C Irritability was not sensitive to these effects. A
majority of subjects enrolled in an open-label extension
study, and some were able to be withdrawn from their
concomitant medications, including from antipsychotics.
Based on these encouraging results from the phase 2
trial, two phase 3 placebo-controlled trials of arbaclofen,
focused on treatment of social avoidance, were done in
adolescents and adults (age 12–50) and in children (age
5–11) with FXS. The decision to conduct simultaneously
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two parallel studies was based upon a sense of urgency
to attempt to obtain FDA approval and make arbaclofen
available as rapidly as possible for the entire age range of
individuals with FXS. Here, we report the results of both
phase 3 trials.
Methods
Participants
Participants were males and females with a DNA-confirmed
FMR1 full mutation aged 12 to 50 years (adolescent/adult
study), and aged 5–11 (child study). The age ranges are
those preferred by FDA for developmental disorders,
with the 5–11 age group representing predominantly
prepubertal children with FXS and the 12–50-year-old
group representing adolescents and adults with FXS for
whom behavioral issues are overall very similar throughout
the age range. Up to three concomitant psychoactive medi-
cations (including antiepileptic drugs), which were FDA-
approved for the condition or symptom being treated, were
permitted, but use of vigabatrin, tiagabine, riluzole, racemic
baclofen was prohibited because of their GABAergic mech-
anisms. Also, participants could not be taking medications
with anxiolytic properties (including serotonin reuptake
inhibitors (SSRIs), tricyclic antidepressants, venlafaxine,
buspirone, benzodiazepines that were administered on a
regular daily schedule, and propranolol). It was not consid-
ered feasible in FXS, a rare condition with severe behavioral
dysfunction, to enroll a cohort in the specified age ranges
with no psychoactive medication treatment that would be
sufficient size for appropriate power to detect drug effect.
Further, allowance of standard-of-care background therapy
would allow identification of effects contributed by
arbaclofen which supersede those obtained from standard
care. Pharmacological treatment regimens were required
to be stable for 4 weeks and educational, behavioral, and
other treatments stable for 2 months, prior to screening
and for the duration of the study. Subjects with any previ-
ous seizure were required to be on anticonvulsant medica-
tion and seizure-free for 6 months or seizure-free for
3 years off of anticonvulsants. A score of 8 or greater on
the parent-rated ABC-C Lethargy/Social Withdrawal sub-
scale was required at the screening visit and visit 1 at the
beginning of the treatment period. This cutoff was used
because it was the median value observed in the prior
phase 2 arbaclofen trial in FXS, and also defined in the
trial post hoc analyses the group that demonstrated signifi-
cant improvement on numerous measures including the
ABC-CFX Social Avoidance subscale. Caregivers watched a
training video explaining how to rate the ABC-C before
performing the rating at screening. Female subjects of
childbearing potential were tested and excluded if they were
pregnant. Female patients were required to follow an
acceptable method of birth control throughout the study.
The major exclusion criteria included, but were not limited
to, impairment of renal function, evidence or history of ma-
lignancy, or any significant hematological, endocrine, car-
diovascular, respiratory, hepatic, or gastrointestinal disease,
and illicit drug use or alcohol abuse. Informed consent was
obtained from the participant or a legal guardian or legally
acceptable representative in all cases, and participants were
enrolled if they met all inclusion criteria. The studies (clin-
icaltrials.gov identifiers NCT01282268 for adolescent/adult
study, NCT01325220 for child study) were approved by the
Institutional Review Boards governing each site.
Study design
The studies were phase 3 randomized, double-blind,
placebo-controlled, multisite, parallel group trials in
adolescent/adults (209FX301, NCT01282268) and children
(209FX302, NCT01325220) with FXS, conducted at 23 sites
between May 2011 and December 2012 (adolescent/adult
study) and 25 sites between June 2011 and June 2013 (child
study) in the USA (Fig. 1 shows design of both studies).
Study design complied with FDA GCP requirements and
followed the standard elements in the CONSORT checklist
guidelines. In the adolescent/adult study, drug was flexibly
titrated every 7 days, starting at 5 mg BID, and then 10 mg
BID, 10 mg TID, and 15 mg TID, until the maximal toler-
ated dose was established. In the child study, participants
were assigned in a ratio of 1:1:1:1 to one of the following
four fixed dose treatment arms: arbaclofen 5 mg BID,
10 mg BID, 10 mg TID, or placebo. Dosing was chosen
based on FDA’s requirement that three parallel dose groups
be enrolled in a placebo-controlled trial (fourth dose group
receiving placebo). In addition, the dose that demonstrated
efficacy in the phase 2 trial post hoc analyses was chosen as
the middle dose and doses 50% lower and 50% higher were
selected for the other two dose groups. Participants allo-
cated to an arbaclofen arm-initiated therapy with 5 mg
daily, and the dose was up-titrated every 7 days in steps
(5 mg BID, 10 mg BID, then 10 mg TID) until the target
dose was reached. Down-titration for dose adjustment was
not allowed due to FDA’s preference for the most stringent
assessment of tolerability; patients unable to tolerate their
assigned dose were discontinued. Randomization was
stratified based upon the use of antipsychotic medication.
The total length of the double-blind treatment period was
8 weeks for both studies, including up-titration and then
stable dosing for at least the final 4 weeks at the MTD
(adolescent/adult study) or assigned fixed dose (child study).
Subjects returned for evaluations 2, 4, and 8 weeks after
initiating double-blind treatment. After the 8-week treat-
ment period, participants entered a withdrawal period,
during which study drug was tapered weekly until off,
according to the reverse of the up-titration schedules
noted above, over 0–3 weeks (adolescent/adult study) or
1–3 weeks (child study). Phone calls occurred every
3–4 days during the first 29 days after randomization, when
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the drug was being titrated upwards; then every 2 weeks,
during the stable dosing period; and then every 4–6 days,
during down-titration at the end of the placebo-controlled
dosing period. Participants returned for a close-out visit
within 3 days of the last dose of study medication (adult/
adolescent study) or at 11 weeks when off study medica-
tion (child study). Subjects who completed the 8-week
double-blind treatment period or who discontinued due
to intolerability to their assigned dose were then eligible
for enrollment in an open-label extension study in
which subjects could be titrated to and treated with
arbaclofen at the best tolerated dose ranging from
5 mg BID to 15 mg TID (209FX303, NCT01555333).
Results from the long-term open-label study will be re-
ported separately.
Efficacy assessments were performed at baseline and
treatment weeks 2, 4, and 8, as well as on phone calls to
the primary caregiver at treatment weeks 1 and 3. Efficacy
assessments on phone calls included only the CGI-I and
CGI-S, which were obtained via an interview with the
caregivers done by the site investigators. Safety and toler-
ability assessments were performed at baseline, treatment
weeks 2, 4, 8 and the follow-up visit (which occurred
3 weeks after the end of treatment at week 8), as well as
on all phone calls, and at 4 weeks after the follow-up visit
for participants not entering the open-label extension.
Families were queried about concomitant treatments and
any changes in medications at every visit and phone call,
in order to identify any emergent medical issues and
ensure psychoactive medications were not being changed.
Study drug and matching placebo were provided as 5
and/or 10 mg orally disintegrating tablets in color-coded
blister packs. The orally disintegrating formulation, which
showed pharmacokinetics similar to racemic baclofen
prior to use in 209FX301 and 209FX302, was developed
for the studies to accommodate patients who could not
swallow pills. Blinding was maintained in the setting of
different doses by requiring subjects to all take the same
number of tablets three times a day which could be either
drug or placebo tablets. Subjects were assigned to
treatment linked to a set of blister packs according to
a centrally generated randomization list. Treatment compli-
ance was monitored with a dosing form, which guardians
completed on a daily basis.
Assessments
Efficacy assessments
All efficacy outcomes were assessed as change from
baseline after 8 weeks of treatment. The primary efficacy
outcome for both studies was the parent or caregiver-rated
Aberrant Behavior Checklist-Community Edition (ABC-C)
refactored for FXS (ABC-CFX) Social Avoidance score.
The key secondary outcome was the Clinical Global
Impression-Improvement (CGI-I). The ABC-CFX Social
Avoidance score was chosen as primary endpoint because
this measure showed improvement in the full intent-to-
treat (ITT) cohort in the phase 2 study and because the
FDA required a primary outcome in one behavioral
domain. Because the drug reversed molecular, electro-
physiological and synaptic phenotypes in the animal
model [11, 17], it was postulated that it should help all
aspects of FXS. Although the company requested,
therefore, to nominate a measure of global function as
the primary endpoint, this was not allowed by FDA.
The FDA rather recommended that a global outcome
measure be implemented as a key secondary rather
than as primary endpoint; hence, the CGI-I was chosen as
such key secondary measure. Furthermore, there was regu-
latory precedent for using the CGI-I (secondary) and the
ABC-C Irritability subscale (primary), in addition to a re-
sponder analysis, for approval of atypical antipsychotics for
irritable behavior in ASD [18]. Other secondary outcomes
were the Clinical Global Impression-Severity (CGI-S), visual
analog scale (VAS) for disruptive and anxiety behaviors,
Fig. 1 Design of adult/adolescent (a) and child (b) phase III arbaclofen studies
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and Vineland Adaptive Behavior Scales, Second Edition
(Vineland-II) - Socialization domain raw and standard
scores (Survey Interview Form with parent/caregiver/
Legally Authorized Representative (LAR)). Exploratory
outcomes were a responder analysis (CGI-I score of 1
or 2, and 10, 20, 25, 30, 40, 50, and 60% improvement
on the ABC-CFX Social Avoidance subscale), the other
ABC-CFX Subscales (including Irritability, Hyperactivity,
Stereotypic Behavior, Lethargy, and Abnormal Speech),
Parenting Stress Index (PSI) – Short Form, Vineland-II
Maladaptive Behavior Index and other domain raw scores,
Vineland-II - Communication domain raw and standard
scores, and Total Score and Daytime sleepiness subscale
of the Children’s Sleep Habits Questionnaire (CSHQ). The
ABC-CFX was performed at baseline and weeks 4 and 8 of
the treatment period. The CGI-I was performed at
baseline and weeks 1, 2, 3, 4, and 8. The CGI-S and
VAS were performed at baseline and weeks 2, 4, and 8.
The Vineland-II, PSI, and CSHQ were performed at
baseline and at 8 weeks.
Safety assessments
Safety and tolerability of STX209 was determined by
adverse events (AEs; all visits and calls), physical examin-
ation, vital signs and weight (all visits), laboratory tests in-
cluding complete blood count (CBC), chemistry panel, and
urinalysis (UA) (baseline and weeks 4 and 8), electrocardio-
gram (ECG; baseline and week 8), and a suicidality assess-
ment (three question interview with subject and parent/
caregiver/LAR, all visits, as required by FDA guidelines).
When the patient could not provide meaningful answers
due to inadequate language or cognitive function, the
family was asked if there was any sign of suicidality.
Pharmacokinetics
Four blood samples for analysis of plasma STX209 were
obtained from each subject at four defined post-dose
time points. Samples were to be used for population-
based pharmacokinetic (PK) analyses, to confirm accurate
randomization, and compliance with use of study medica-
tion. The goal was to perform an integrated population PK
analyses with data from the phase 2 and 3 and open-label
extension trials; however, these analyses were not com-
pleted prior to the wind-down of Seaside Therapeutics.
Description of assessments
DSM-IV-TR Diagnostic and Statistical Manual of Mental
Disorders IV – Text Revision (DSM-IV-TR) (APA 2000)
criteria for Pervasive Developmental Disorders (PDD), in-
cluding severe and pervasive impairment in several areas of
development: reciprocal social interaction skills, communi-
cation skills, and the presence of stereotyped behavior,
interests, and activities, were used by an Investigator on the
study to determine at the screening visit if the subject had a
PDD in addition to FXS.
ABC-C The ABC-C is a 58-item parent-rated global
behavior checklist implemented for the measurement
of drug and other treatment effects in individuals with
intellectual disability, and utilized in registration studies for
drug efficacy in autism spectrum disorder [18]. In its ori-
ginal validation, five empirically derived dimensions were
identified: Irritability, Lethargy/Social Withdrawal, Inappro-
priate Speech, Hyperactivity, and Stereotypic Behavior. The
Lethargy/Social Withdrawal scale includes questions about
social indifference, social avoidance, and physical lethargy
[19]. A recent factor analysis of the ABC specifically in FXS
(ABC-CFX) [16] generated a six-factor structure modifying
items mapping to most subscales and identified a “Social
Avoidance” factor that is related to the original “Lethargy/
Social Withdrawal” scale, but which does not include the
items assessing social indifference or physical lethargy.
These items are now in a new subscale labeled Socially
Unresponsive/Lethargic.
CGI-S The CGI-S is a clinician-rated measure used to
assess the impairment of neurobehavioral function in
study subjects. The clinician should consider all aspects
of that function, including but not limited to, internalizing
and externalizing problems, and social engagement. The
clinician’s score utilized the following 7-point Likert scale:
normal (not at all impaired), borderline, mild, moderate,
marked, severe, or extreme.
CGI-I The CGI-I is a well-validated clinician-rated
measure commonly used in drug studies [20] because it
allows the clinician to integrate all sources of information,
including the parent/caregiver history, observations in the
clinic, and reports from other sources, into a single rating
of improvement during treatment. For these studies, the in-
vestigator considered all aspects of the subject’s neurobe-
havioral function, including but not limited to internalizing
problems, externalizing problems, and social engagement,
and rated the scale employing a 7-point Likert scale: very
much improved, much improved, minimally improved, no
change, minimally worse, much worse, very much worse. In
these studies, a single clinician-investigator at the site rated
the CGI for each subject. This individual was not blinded
to side effects or results of other measures, as it was not
thought a priori that these would be unblinding based on
the side effect profile from the phase 2 trial. Investigators
were trained on CGI-I and CGI-S rating to standardize the
rating of participants, including rating practice cases prior
to performing the measure in the trials.
Vineland-II The Vineland-II [21] is designed to assess
the personal and social functioning of handicapped and
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non-handicapped persons. It is a gold standard for the
assessment of adaptive functioning, and, with IQ testing,
comprises one of two pillars for the assessment and
diagnosis of intellectual disability. The “Survey Interview
Form” of the Vineland-II was administered by a qualified
psychologist or experienced rater to a parent or care-
giver using a semi-structured interview format. Only
the Communication domain, Socialization domain, and
Maladaptive Behavior Index were completed (not the
Daily Living Skills and Motor Skills domains).
VAS-Anxiety and Disruptive Behaviors This method-
ology has been utilized in autism [18, 22]. The parent/
caregiver/LAR is asked about the severity of anxiety and
disruptive troublesome behaviors and is given examples
of several of each of these types of target behaviors and
then rates changes in severity of the anxiety and disruptive
behavior target symptom on separate visual analog scales
(VASs). The VAS is a 10-cm line, with troublesome behav-
iors anchored on one end with the description “worst
ever” and on the other end with “no problem at all”. This
scale showed good reliability in a prior study of subjects
with FXS [23].
PSI – Short Form The PSI [24] provides a measure of
parental stress and is widely used in the assessment of
family function for families with children who have special
needs. The PSI was normed on over 2500 parents, and the
36-item short form provides a well-validated estimate of
the overall stress faced by parents.
CSHQ The CSHQ is a 35-item questionnaire designed
for children aged 4 through 12 years, to screen for the
most common sleep problems in that age group. Reliability
and validity data has been collected on a sample of 495
elementary school children and on a clinical sample from a
pediatric sleep clinic [25].
Suicidality assessment This semi-structured interview
of the parent/caregiver/LAR and subject was completed
by a physician or clinical psychologist. A targeted set of
questions were asked to assess potential suicidality. At a
minimum, the clinician asked the subject the following
questions: Do you ever wish you were dead? Have you
done anything to hurt yourself? Then the clinician asked
the parent/caregiver/LAR the following question: Has
(subject’s name) done anything to hurt himself/herself
(other than stereotyped self-injurious behaviors)?
Statistical analysis
For both studies, the ABC-CFX Social Avoidance score
was designated the primary endpoint based on the phase
2 study results [15]. All data collected in this study was
documented using summary tables, figures, and subject
data listings. All efficacy analyses were based on an intent-
to-treat (ITT) population defined as all randomized sub-
jects who were assigned to study medication, received at
least one dose of double-blind study medication, and had
post-baseline efficacy data available. For the primary effi-
cacy variable of the ABC-CFX Social Avoidance score, a per
protocol (PP) population was also defined as those ITT
subjects who fulfilled the entrance criteria and substan-
tially adhered to the protocol for the duration of the
study. Differences in efficacy variables from baseline to
the end of 8 weeks of double-blind treatment in the arba-
clofen treatment group and placebo treatment group were
assessed using Restricted Maximum Likelihood (REML)-
based Analysis of Covariance (ANCOVA) techniques for
continuous variables and chi-square techniques for categor-
ical variables as appropriate. Baseline scores and age were
co-variates in the analyses. For all comparisons, a nominal
p value of 0.05 or less was required to declare significance,
and no adjustments for multiplicity were made. For the
adolescent/adult study, there was one primary comparison
of active versus placebo. For the child study, the level of sig-
nificance for the primary efficacy comparison was protected
using a closed testing procedure (that allows simultaneous
testing of several hypotheses). In addition, only one key
secondary efficacy variable was declared for each study.
The Safety Populations were comprised of all subjects
who took at least one dose of study medication. Clinical
safety was addressed by calculating the incidence of AEs
in the two treatment groups and by descriptively sum-
marizing laboratory assessments, physical examinations,
ECG assessments, and vital signs.
Sample size
Study group sizes were based upon formal power analyses
that identified the minimum number of subjects required
to detect a medium effect size. Specifically, it did not
appear smaller trials would be worth running as smaller
group sizes would not be sufficiently powered to assess
efficacy. For the primary outcome, the ABC-CFX Social
Avoidance subscale, the adolescent/adult study was de-
signed to have at least 80% power to detect a treatment
effect of size 0.55, with a p level of 0.05 in a sample size of
(n = 60) subjects per group. The child study was designed
to have at least 80% power to also detect a medium treat-
ment effect of size 0.57, with a p level of 0.05 in a sample
size of (n = 50) participants per group in each of the four
dose arms.
Results
Demographic and background characteristics
A total of n = 125 adolescent/adult participants and n = 172
children with FXS were randomized into the two treatment
arms (adolescents/adults) and four treatment arms
(children) of each trial (Fig. 2, Tables 1 and 2). Enrollment
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in the child study had to be halted early for financial
reasons and thus the projected sample size of 200 patients
was not enrolled. Overall, n = 119 participants completed
the adolescent/adult study and n = 159 completed the
child study. A total of n = 13 subjects discontinued due to
AEs, including two in the adolescent/adult study (both in
the active treatment arm) and 11 in the child study (one
in the placebo, four in the 5 mg BID, three in the 10 mg
BID, and three in the 10 mg TID groups) (Fig. 2). The
remaining discontinuations in the adolescent/adult study
were due to protocol violation (one in treatment arm) and
lost to follow-up (two treatment arm, one placebo), and in
the child study were due to consent withdrawal or
protocol violation (one each in 10 mg TID group). Protocol
violations included dispensing the wrong kit for the adult/
adolescent study subject and failure to meet inclusion/
exclusion criteria in the child study subject.
In each study, participants’ demographic and background
characteristics in the ITT population were generally com-
parable across the treatment groups (Tables 1 and 2). The
mean age was about 19 years in the adolescent/adult study
(range 12–48 years) and about 8 years (range 5–11 years)
in the child study. In both trials, the majority of randomized
patients were White non-Hispanic (77 and 78.5% in
adolescent/adult and child studies, respectively). The
higher proportion of males in both studies (79.2 and
Fig. 2 Consort diagrams for adult/adolescent (a) and child (b) phase III arbaclofen studies
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83.7% in adolescent/adult and child studies, respectively) is
a result of the reduced penetrance of FXS in females due to
expression of the normal gene on the unaffected X
chromosome. About 73% of adolescents/adults and
79% of children met clinical (DSM-IV) criteria for autism
spectrum disorder (ASD). Baseline ABC-CFX Social Avoid-
ance scores were very similar across treatment groups,
ranging from 7.6 to 7.9 in the adolescent/adult groups and
from 6.4 to 6.9 in the child groups. Overall 20 and 18% of
the adolescent/adult and child participants, respectively,
were on antipsychotics, reflecting similar levels of usage
in the two studies; however, there was some variability
in antipsychotic use between the child groups, ranging
from 9.6 to 26.7%, with the most antipsychotic use in
the placebo group and the least in the 10 mg BID group
(Tables 1 and 2).
Adolescent/adult study efficacy results
The adolescent/adult study did not meet the primary ob-
jective of showing efficacy in reducing the ABC-CFX Social
Table 1 Demographics. Adult/adolescent study
Group/characteristic Placebo (N = 63) Arbaclofen (N = 62) Total (N = 125)
Mean age (SD) 18.7 (7.22) 19.0 (6.73) 18.9 (6.96)
Age group (adolescents age 12–17) 36 (57.1%) 31 (50.0%) 67 (53.6%)
Gender (males) 49 (77.8%) 50 (80.6%) 99 (79.2%)
Race/ethnicity
White non-hispanic 50 (79%) 47 (76%) 97 (77%)
White hispanic 4 (6.5%) 5 (8.1%) 9 (7.2%)
African American 6 (9.5%) 5 (8.1%) 11 (8.8%)
Asian 1 (1.6%) 1 (1.6%) 2 (1.6%)
Other 2 (3.2%) 4 (6.5%) 6 (4.8%)
Concomitant medications
Any psychotropic medications 40 (63.5%) 35 (56.5%) 75 (60.0%)
Antipsychotics 11 (17.4%) 14 (22.6%) 25 (20.0%)
None 23 (36.5%) 27 (43.5%) 50 (40.0%)
DSM-IV diagnosis of ASD 45 (71.4%) 46 (74.2%) 91 (72.8%)
Mean ABC-CFX Social Avoidance score (SD) 7.9 (3.48) 7.6 (3.17)
Table 2 Demographics. Child study
Group/characteristic Placebo
(N = 45)
Arbaclofen Total
(N = 169)5 mg BID (N = 41) 10 mg BID (N = 41) 10 mg TID (N = 42)
Mean age (SD) 8.0 (2.20) 7.5 (1.86) 7.5 (1.81) 8.1 (2.02) 7.8 (1.99)
Gender (males) 38 (84.4%) 35 (83.3%) 35 (83.3%) 36 (83.7%) 144 (83.7%)
Race/ethnicity
White non-hispanic 38 (84.4%) 29 (69.0%) 32 (76.2%) 36 (83.7%) 135 (78.5%)
White hispanic 2 (4.4%) 2 (4.8%) 4 (9.5%) 3 (7.0%) 11 (6.4%)
American Indian or Alaska Native 0 1 (2.4%) 0 0 1 (0.6%)
African American 2 (4.4%) 2 (4.8%) 1 (2.4%) 1 (2.3%) 6 (3.5%)
Asian 1 (2.2%) 3 (7.1%) 0 1 (2.3%) 5 (2.9%)
Other 2 (4.4%) 5 (11.9%) 5 (11.9%) 2 (4.7%) 14 (8.1%)
Concomitant medications
Any 33 (73.3%) 34 (81.0%) 28 (66.7%) 32 (74.4%) 127 (73.8%)
Antipsychotics 12 (26.7%) 9 (21.4%) 4 (9.6%) 6 (14.0%) 31 (18.0%)
None 12 (26.7%) 8 (19.0%) 14 (33.3%) 11 (25.6%) 45 (26.2%)
DSM-IV diagnosis of ASD 34 (75.6%) 32 (76.2%) 35 (83.3%) 35 (81.4%) 136 (79.1%)
Mean ABC-CFX Social Avoidance score (SD) 6.9 (3.49) 6.9 (2.84) 6.9 (3.03) 6.4 (2.92)
BID twice daily, TID three times daily, SD standard deviation, ASD autism spectrum disorder, ABC-CFX Aberrant Behavior Checklist refactored for FXS
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Avoidance score after 8 weeks of treatment (Table 3)
nor was there significant evidence of efficacy on any
other measure including the CGI-I, CGI-S, VAS for disrup-
tive and anxiety behaviors, Vineland-II - Socialization do-
main raw or standard scores, responder analysis, other
ABC-CFX subscales, PSI, Vineland-II Maladaptive Behavior
Index, Vineland-II - Communication domain raw and
standard scores, and Total CSHQ Score and Daytime
sleepiness subscale. The CGI-S showed a trend toward
improvement over placebo in the arbaclofen group (p =
0.063) but this was the only measure showing a strong
trend, and given the multiple comparisons, this result
alone is difficult to interpret as meaningful. The sub-
group with co-morbid ASD also did not show benefit
for arbaclofen over placebo.
Child study efficacy results
The child study did not meet the primary objective of
showing efficacy in reducing the ABC-CFX Social Avoid-
ance score after 8 weeks of treatment (Table 4) in any
dosing group. However, there was a strong trend toward
improvement (Fig. 3) on this measure in the highest
dose (10 mg TID) arbaclofen group over placebo (p =
0.085, effect size 0.24). This dose group (10 mg TID) at
8 weeks also showed nominally significant improve-
ment (Fig. 4) for both the ABC-CFX Irritability subscale
(p = 0.031, effect size 0.51) and the Parenting Stress
Index (p = 0.032, effect size 0.42), and trends toward
improvement on the ABC-CFX Hyperactivity subscale
(p = 0.081, effect size 0.44) and the CGI-I (p = 0.119,
effect size 0.43) (Fig. 5a). The Pearson Product Moment
correlation coefficient for change during the 8 weeks of
treatment for the ABC-CFX Irritability subscale and PSI, the
two measures with the highest significance for improve-
ment on 10 mg TID arbaclofen, was 0.313 (p < 0.001). Sub-
stantial placebo effects were evident (Tables 4 and 5), and
the lower dose groups did not show significant improve-
ment for arbaclofen over placebo on any measure. Both the
percent of predefined responders (those subjects with 25%
improvement in the primary outcome ABC-CFX Social
Avoidance plus a CGI-I of 1 or 2) (Fig. 5b) and the CGI-I
showed possible dose responses, with a numerically larger
response as the dose increased although given the small
cohort size these response trends did not achieve statistical
Table 3 Efficacy measures at baseline and week 8 in ITT population for Adolescent/adult study
Measure Placebo N = 63 (62 completers) Arbaclofen N = 62 (57 completers)
Baseline Week 8 Change Baseline Week 8 Change p
ABC-CFX SA 7.9 (3.48) 5.5 (3.37) −2.4 (0.32) 7.6 (3.17) 5.3 (3.57) −2.3 (0.33) 0.974
ABC-CFX I 15.8 (13.18) 10.8 (11.01) −5.3 (0.88) 16.9 (14.58) 12.3 (12.35) −4.2 (0.89) 0.421
ABC-CFX H 11.2 (7.32) 8.0 (6.75) −3.4 (0.57) 12.9 (8.44) 8.7 (6.82) −3.6 (0.58) 0.811
ABC-CFX SB 8.4 (5.77) 6.0 (5.30) −2.5 (0.40) 8.8 (5.37) 5.7 (4.84) −2.9 (0.40) 0.508
ABC-CFX L 12.3 (6.70) 7.3 (5.38) −5.2 (0.56) 12.8 (7.19) 7.9 (5.94) −4.7 (0.57) 0.536
ABC-CFX IS 6.4 (3.74) 4.6 (3.02) −1.8 (0.28) 6.5 (3.90) 4.8 (3.53) −1.5 (0.29) 0.452
CGI-I – 3.1 (0.12) – – 3.2 (0.12) – 0.587
CGI-S 4.7 (0.92) 4.4 (0.98) −0.3 (0.08) 4.6 (1.07) 4.1 (1.06) −0.5 (0.08) 0.063
Responder – 25.00% – – 24.10% – 0.913
PSI 126.5 (20.45) 129.1 (23.26) 4.1 (2.23) 115.4 (22.04) 120.2 (22.48) 3.3 (2.27) 0.816
VAS-Anx 59.9 (24.57) 39.1 (26.82) −21.2 (33.31) 62.0 (27.00) 46.4 (29.96) −14.7 (3.38) 0.176
VAS-Dis 32.9 (28.75) 27.4 (24.74) −7.0 (2.67) 37.6 (33.40) 33.3 (29.57) −3.9 (2.72) 0.413
Vineland-II Soc 55.2 (20.33) 57.4 (19.70) 2.5 (1.17) 53.4 (15.80) 53.5 (18.17) 0.1 (1.17) 0.151
Vineland-II Comm 51.4 (20.91) 53.4 (20.56) 1.9 (1.06) 48.5 (18.54) 48.9 (19.72) 0.2 (1.06) 0.274
Vineland-II Mal 19.6 (1.43) 19.1 (1.27) −0.6 (0.16) 20.0 (1.77) 19.2 (1.77) −0.7 (0.16) 0.638
CSHQ-T 42.4 (6.68) 41.1 (5.83) −1.3 (0.44) 42.7 (7.55) 41.1 (6.60) −1.4 (0.45) 0.857
CSHQ-DS 10.8 (2.26) 10.7 (2.49) −0.2 (0.25) 11.0 (2.83) 10.7 (2.49) −0.3 (0.26) 0.700
Completers are those who finished the 8-week treatment period and assessments. All baseline, week 8 and change values given as mean (SE) for the group,
except responder values which are given as percent responders out of total group, p values are for adjusted mean changes relative to the placebo group and
adjusted mean changes are shown in the table
ABC-CFX Aberrant Behavior Checklist refactored for FXS; SA Social Avoidance subscale, I Irritability subscale, H Hyperactivity subscale, SB Stereotypic Behavior
subscale, L Socially Unresponsive/Lethargic subscale, IS Inappropriate Speech subscale, CGI-I Clinician Global Impression of Improvement, CGI-S Clinician Global
Impression of Severity, Responder percent of participants with at least a 25% improvement on the ABC-CFX Social Avoidance primary outcome and a CGI-I of 1
(very much improved) or 2 (much improved) at 8 weeks, PSI Parenting Stress Index, VAS-Anx Visual Analog Scale for Anxiety, VAS – Dis Visual Analog Scale for
Disruptive Behaviors, Vineland-II Soc Vineland Adaptive Behavior Scales, Second Edition Socialization domain standard score, Vineland-II Comm Vineland Adaptive
Behavior Scales, Second Edition Communication domain standard score, Vineland-II Mal Vineland Adaptive Behavior Scales, Second Edition – Maladaptive Behavior
Index standard score, CSHQ-T = Children’s Sleep Habits Questionnaire – Total score, CSHQ-DS = Children’s Sleep Habits Questionnaire - Daytime
Sleepiness subscale
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significance. There were no significant effects in the
highest dose group at 4 weeks, indicating effects were
likely dependent on length of treatment. While taken
together these trends and nominally significant results
suggest a signal for drug effect, none of the effects were
significant after correction for multiple comparisons.
There was no improvement in any dose group for
arbaclofen over placebo in the CGI-S, ABC-CFX So-
cially Unresponsive/Lethargic, Stereotypic Behavior or
Inappropriate Speech subscales, VAS for Anxiety, VAS
for Disruptive Behaviors, Vineland-II - Socialization
domain raw or standard scores, Vineland-II Maladaptive
Behavior Index, Vineland-II - Communication domain raw
and standard scores, and Total CSHQ Score and Daytime
sleepiness subscale (Table 4). Analyses were performed by
gender on the primary outcome for both the adult/adoles-
cent and child studies and no significant effect of gender
was found. In the child study, the cohort size was felt to be
too small to analyze the subgroup with a co-morbid
diagnosis of ASD for effects of arbaclofen in the highest
dose group versus placebo.
Safety results
The incidence of any treatment-emergent adverse events
(AEs; Table 5) experienced by participants during the
double-blind treatment period was similar in the arbaclofen
and placebo groups (adults/adolescents: 40 (63.5% of partic-
ipants) vs. 45 (72.6%), children on 10 mg TID dose: 34
(75.6%) vs. 35 (81.4%)). In children on the arbaclofen 5 mg
BID and 10 mg BID, the incidence of any AEs was 35
(83.3%) and 39 (92.9%), respectively, reflecting lack of a
dose relationship. Most reported AEs were mild in severity.
AEs during the double-blind treatment period are shown in
Table 5. In the adolescent/adult study, the most com-
monly experienced AEs were headache, nausea, vomiting,
anorexia, irritability, anxiety, agitation, and upper respira-
tory infection (URI). All of these except URI were numeric-
ally more frequent in the arbaclofen group although no AE
had an incidence of over 15%. In the child study the most
commonly experienced AEs for the 10 mg TID, the highest
dose group, were vomiting, aggression, URI, headache,
rhinorrhea, nasal congestion, anxiety, insomnia, ear infec-
tion, and gastroenteritis. All of these except aggression, agi-
tation, irritability, nausea, and URI were numerically more
frequent in the highest dose arbaclofen group, although
diarrhea, nasal congestion, anxiety, decreased appetite, and
gastroenteritis were not dose related. Nausea, diarrhea,
irritability, anxiety, insomnia, decreased appetite, ear in-
fections, and gastroenteritis were all numerically slightly
more frequent in the lower dose (5 and 10 mg BID) groups
than in the placebo group (Table 5). Vomiting (30.3%) was
the highest frequency side effect in the highest dose group,
followed by aggression at 16.3% (placebo aggression inci-
dence was 17.8%) and all other AEs had an incidence of less
than 12%.
In the adolescent/adult study, there were two AEs
leading to discontinuation, depressed mood, and psychotic
disorder, both occurring in the arbaclofen group. In the
child study there were 11 AEs leading to discontinuation
(10 in an arbaclofen group and 1 in the placebo group).
These were aggression/irritability (placebo group); anxiety,
staring, and aggression (10 mg TID group); aggression,
staring, and anxiety (10 mg BID group); and agitation
(two participants), hyperactivity, and irritability (5 mg BID
group). There were no clinically relevant changes in vital
signs, weight, ECGs, or laboratory test results in any of
the treatment groups in either study. There were no
serious AEs or AEs related to suicidality in either trial and
overall arbaclofen was well tolerated.
Discussion
These trials represent the advanced stages of an effort at
translating to humans with FXS the basic science and
preclinical findings from the Fmr1 knockout mouse,
which suggested a potential therapeutic role of GABA-B
agonists in ameliorating pathophysiology linked to exces-
sive protein synthesis and/or diminished inhibition. The
design of the studies was based on a phase 2 trial that had
indicated benefits in social avoidance in patients with FXS
treated with arbaclofen [15]. Unfortunately, neither the
Fig. 3 Baseline and end-of-treatment scores (a) and change in
scores (b) for the primary outcome measure, the ABC-FX-Social
Avoidance subscore, in child study for placebo and highest dose
(10 mg TID) arbaclofen groups
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adolescent/adult nor the child study met the primary
outcome.
Interpretation of trial results
The groups enrolled in the studies seemed representative
of the FXS population from a demographic standpoint.
However, the rates of ASD were on the high end in com-
parison to previous studies [26, 27]. This is likely because
the study enrolled based on social withdrawal, eliminating
patients with better socialization. The male to female ratio
was typical of most FXS studies performed in gender-
mixed populations, with fewer females because they are
less affected. Concomitant medication use was high over-
all but somewhat higher in the younger group, reflecting
greater severity of behavior problems in the child study.
Antipsychotic use was not particularly high in either
group. However, as in most FXS cohorts, use was
higher in the older population [28].
The adult/adolescent study did not show evidence of
benefit for arbaclofen. However, the child study showed
nominally significant improvement in several measures and
dose-related trends for the primary and several secondary
outcomes, suggesting a signal for a beneficial effect of
the drug in the highest dose group. Specifically, nominally
significant improvement was seen in the ABC-CFX Irrit-
ability behavioral measure, which has been strongly linked
to quality of life for FXS families in other studies [29]. A
corresponding statistically correlated improvement in the
parenting stress index (PSI) in the child study reported
here is supportive evidence of potential benefit. This can
be viewed as a potentially clinically meaningful result con-
sidering that the study involved only about 40 participants
per group in placebo and comparison treatment groups.
The primary outcome measure, ABC-CFX Social Avoid-
ance, showed a trend toward improvement that did not
reach statistical significance. It is important to consider
that the original power analysis estimated that 50 patients
per group would be required to achieve statistical signifi-
cance with a medium effect size. The study closed early
for financial reasons and the groups were not fully en-
rolled. Although none of the significant effects identified
would survive correction for multiple comparisons, the
likelihood they are meaningful is increased considering
the effect sizes and the fact that efficacy on the measures
with the highest significance in the highest dose group
tracked together. We suggest the trends for improvements
observed on numerous outcome measures (ABC-CFX
Irritability, Social Avoidance and Hyperactivity subscales,
Fig. 4 Baseline and end-of-treatment scores (a, c) and change in scores (b, d) for the ABC-FX-Irritability subscale (a, b) and Parenting Stress Index
(b, d), in child study for placebo and highest dose (10 mg TID) arbaclofen groups. Standard error bars represent standard error of the mean
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the PSI and CGI-I) may represent therapeutic benefit of
arbaclofen, particularly considering the variability in be-
havioral impairment in FXS and that there were no trends
for worsening on any outcome measure.
It is noteworthy that the child study reported here is
the first placebo-controlled trial conducted in FXS to
date that has shown a nominally significant improvement
in the ABC-CFX Irritability or ABC-I (Irritability scale from
original ABC-C), the primary efficacy endpoint for approval
of antipsychotics in idiopathic ASD [18]. The failure to
observe an improvement in the adolescent/adult study
is possibly explained by the fact that the younger par-
ticipants in the child study had a higher level of base-
line irritability and, thus, it may have been easier to
observe a response in this group. We also note that the
average Vineland-II scores were higher in the children
relative to the adolescents and adults. In a concurrent
study of arbaclofen in idiopathic ASD, higher function-
ing individuals were found to have a greater drug re-
sponse [30]. Alternatively or in addition, it is possible
that disease modification with such a brief treatment
occurs far more readily in the developing brain, prior
to adolescence.
The drug effect sizes for multiple measures in the child
study, including the ABC-CFX Irritability, PSI, CGI-I, ABC-
CFX Social Avoidance, and ABC-CFX Hyperactivity, between
0.24 and 0.51, were comparable or greater than the effect
sizes observed in trials submitted to FDA for approved and
marketed antidepressants (mean 0.31 [range 0.17–0.42])
[31]. In fact, to be able to detect a difference at 80% power
with 38 subjects per group on the primary outcome, the
ABC-CFX Social Avoidance subscale, an effect size of 0.65
would be needed (n = 40, effect size 0.63), a higher effect size
than seen for most marketed psychotropic drugs. Effect sizes
for risperidone [18] in ASD were higher on the ABC-C Irrit-
ability subscale at 1.2, although only 0.4 for the ABC-C
Social Withdrawal subscale. However, while the risperidone
study was conducted in the absence of concomitant medica-
tion for co-morbid behavioral diagnoses, in this study arba-
clofen achieved the aforementioned effect sizes over and
above treatment with optimized concomitant medica-
tions to manage behavior, and in about a quarter of
cases, in addition to therapy with risperidone or aripi-
prazole. The allowance of concomitant medication used
for approved indications to treat co-morbid diagnoses
in FXS is expected to confound and reduce observable
efficacy of arbaclofen, yet allows identification of effects
contributed by arbaclofen which supersede those ob-
tained from standard care. Furthermore, the scientific
rationale for development of arbaclofen was based upon
the ability to correct the underlying molecular pertur-
bations, not a specific behavior, and the conceptual
treatment target was really the full FXS phenotype. The
trial results are consistent with this concept in that
beneficial effects were distributed across multiple behaviors
and effect sizes and increased with longer durations of
treatment. Additionally, the apparent dose dependence of
numerical improvement on ABC-CFX Irritability, ABC-CFX
Social Avoidance, CGI-I, and the responder analysis suggest
that higher doses have the potential to provide even greater
benefit. The excellent tolerability observed with all doses in
both studies, and the lack of a substantially higher fre-
quency of adverse events or study discontinuation at higher
doses in the child study, suggest it would be safe to explore
efficacy at higher doses in future studies of arbaclofen in in-
dividuals with FXS. However, dropouts for side effects may
have been dose-dependent in the child study. Thus, the lack
of an option to down-titrate for dose adjustment in this
study was another limitation that may have reduced the
ability to detect beneficial effects of arbaclofen.
Outcomes measurement as a challenge to translation
A potential limitation related to clinician CGI ratings
and thus responder analyses in this study is the lack of
blinding of CGI raters to adverse events. However, as
seen in Table 5, side effects were not sufficiently more
common in the arbaclofen groups over placebo to unblind
Fig. 5 Dose responses for change in the CGI-I (a) and percent
responders in responder analysis (b) in child study. Responders
are defined as subjects with 25% improvement in the primary
outcome ABC-CFX Social Avoidance plus a CGI-I of 1 or 2
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the investigators. Although raters underwent training to
rate individuals with FXS on the CGI-S and CGI-I, a fur-
ther limitation of the clinician CGI ratings in these studies
was the lack of formal anchors and inter-rater reliability
requirements for raters before performing ratings in the
trials.
The ABC-CFX scale may be adequate for detecting
behavioral effects, as seen for the ABC-CFX Irritability
scale in the arbaclofen child study. Nonetheless, there
are problems with these scales, particularly if the same
scale is used both to qualify for study participation and
as a primary outcome measure. Families may exaggerate
symptoms in the domain required to get into the trial and
then “regression to the mean” leads to large placebo effects
during the trial. This may partially explain why in the previ-
ous phase 2 arbaclofen study, in which enrollment was
based on ABC-C Irritability, subjects showed improvement
over placebo in ABC-CFX Social Avoidance but not
Irritability [15]. The large placebo effect on Irritability in
that study may have rendered a drug effect impossible to
detect. Conversely, enrollment in the phase 3 child study
here was based on ABC-CFX Social Avoidance, and the
improvement on arbaclofen relative to placebo was greater
for the Irritability than for the Social Avoidance subscale.
This experience illustrates the potential for high placebo
response rates when utilizing parent-rated outcome
measures. There is a clear need to explore whether alter-
native enrollment strategies can reduce placebo re-
sponse rates, to develop and validate alternative
outcome measures, and to use study designs that address
exaggerated enrollment scores (e.g., placebo lead-in).
In general, placebo effects in typically developing children
and in neurodevelopmental disorders are large and may
consequently mask results. They may also be correlated
with severity of externalizing problems (e.g., aggression)
and parental expectations. Clinician-ratings are potentially
less susceptible than parent-ratings to these issues; thus, it
may be better to use clinician-anchored scales when pos-
sible, although truly objective measures would presumably
be even better and are badly needed for future FXS trials,
especially in areas like language, cognition, daily living
skills, and social function (also discussed in Budimirovic
et al., this issue [32]). As a result of the recognition of pla-
cebo response and variability problems with parent-rated
measures in these and other early large trials in FXS,
subsequent trials have moved away from use of parent-
rated forms and have incorporated a larger emphasis on
clinician-rated measures including the Vineland-II [33],
the Pediatric Anxiety Rating Scale [34], and a Fragile X
Syndrome Rating Scale [35]. Ongoing validation studies
are underway for measures involving direct observation or
testing in FXS, such as expressive language sampling [36]
Table 5 Treatment-emergent adverse events (AEs) from baseline to week 8, by treatment (safety population)
Adolescent/adult study Child study
Event Placebo Arbaclofen Placebo Arbaclofen 5 mg BID Arbaclofen 10 mg BID Arbaclofen 10 mg TID
n (%) n (%) n (%) n (%) n (%) n (%)
N = 63 N = 62 N = 45 N = 42 N = 42 N = 43
Any adverse event 40 (63.5) 45 (72.6) 34 (75.6) 35 (83.3) 39 (92.9) 35 (81.4)
Vomiting 3 (4.8) 9 (14.5) 8 (17.8) 5 (11.9) 7 (16.7) 13 (30.2)
Aggression 1 (1.6) 2 (3.2) 8 (17.8) 0 (0.0) 5 (11.9) 7 (16.3)
Headache 6 (9.5) 9 (14.5) 3 (6.7) 1 (2.4) 2 (4.8) 5 (11.6)
Nausea 1 (1.6) 6 (9.7) 0 (0.0) 1 (2.4) 2 (4.8) 0 (0.0)
Diarrhea 3 (4.8) 5 (8.1) 3 (6.7) 5 (11.9) 5 (11.9) 5 (11.6)
URI 8 (12.7) 5 (8.1) 6 (13.3) 4 (9.5) 2 (4.8) 5 (11.6)
Rhinorrhea 2 (3.2) 1 (1.6) 2 (4.4) 2 (4.8) 2 (4.8) 4 (9.3)
Nasal congestion 0 (0.0) 2 (3.2) 2 (4.4) 3 (7.1) 2 (4.8) 3 (7.0)
Irritability 4 (6.3) 6 (9.7) 2 (4.4) 3 (7.1) 3 (7.1) 2 (4.7)
Agitation 2 (3.2) 5 (8.1) 3 (6.7) 3 (7.1) 3 (7.1) 2 (4.7)
Anxiety 1 (1.6) 5 (8.1) 1 (2.2) 4 (9.5) 6 (14.3) 3 (7.0)
Terminal insomnia 0 (0.0) 0 (0.0) 1 (2.2) 2 (4.8) 2 (4.8) 3 (7.0)
Middle insomnia 0 (0.0) 0 (0.0) 1 (2.2) 1 (2.4) 2 (4.8) 3 (7.0)
Decreased appetite 0 (0.0) 4 (6.5) 1 (2.2) 3 (7.1) 1 (2.4) 2 (4.7)
Ear infection 1 (1.6) 0 (0.0) 0 (0.0) 2 (4.8) 2 (4.8) 3 (7.0)
Gastroenteritis 0 (0.0) 2 (3.2) 0 (0.0) 2 (4.8) 1 (2.4) 3 (7.0)
Convulsion 1 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
BID twice daily, TID three times daily, URI upper respiratory infection
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and the NIH Toolbox cognitive battery [37], and these
types of measures have been increasingly incorporated in
subsequent trials, including the KiTAP computerized
executive battery [38] and expressive language sampling.
In addition, objective biomarkers to demonstrate target
engagement such as eye tracking [39, 40] and event-
related potentials are being incorporated into proof-of-
concept trials.
The results of the child study may suggest a certain
specificity of arbaclofen effects for irritability in FXS.
However, there are alternative explanations related to
the attributes of the ABC-CFX and other outcome mea-
sures employed in these studies. Parents seem to be more
reliable reporters of severely irritable/aggressive behavior
than other types of behavior (e.g., social). Furthermore,
the FXS-specific factor analysis of the ABC-C led to a new
subscale, the ABC-CFX Social Avoidance subscale. Never-
theless, the latter was reduced to only four questions (i.e.,
Seeks isolation, Withdrawn, Isolates self, Prefers to be
alone). While the validity of the ABC-CFX Social Avoid-
ance subscale is supported by a previous observational
study categorizing social withdrawal behaviors in FXS
[41], the limited number of behaviors in the ABC-CFX
Social Avoidance is likely to reduce its sensitivity for
detecting improvements over time.
It is possible that in the reported FXS trials multiple
domains improved in responders, but with variable mag-
nitude reflecting the individual variability in severity of
core and associated features in FXS. It would be optimal
to be able to measure the drug effect across multiple
domains to capture this potentially variable response. In-
deed, an “autopsy” of the arbaclofen phase 3 FXS trials,
focused on differentiating drug and placebo response
characteristics, suggested that improvements on arbaclofen
were not fully reflected by the outcome measures utilized
in the trials [42]. Specifically, it appears that improvements
in several domains were not captured and future trials may
benefit by including assessments of language and cognition.
In this informal analysis, improvement in the ability to
avoid a maladaptive response to a situation perceived by
the FXS child as overwhelming or aversive (families often
referred to this as “coping”) was the response characteristic
most enriched in the arbaclofen responses relative to pla-
cebo responses. One can imagine a construct in which such
maladaptive responses may result in aggression, social
avoidance and/or hyperactivity in different individuals for
different situations. Consequently, if arbaclofen increased
the ability to deal adaptively with, or decreased the percep-
tion of aversiveness of, previously challenging settings and
situations, improvement in several behavioral domains
would be expected as a part of a single therapeutic effect.
Thus, diversity of symptoms and drug benefits that map
into different domains in different situations and patients
complicate assessments in FXS trials. Obviously, animal
studies based on improvements in synaptic function pro-
vide little guidance on the best measures of improvement
in humans. Therefore, it will be important to develop
methods for measuring and analyzing drug response that
will cover multiple affected domains in humans.
New designs and paradigms to assess validity of effects
in animal models
The relatively weak statistical trends seen only in the
child trial raises the possibility that the etiologic model
could be wrong and that mGluR5- and GABA-related
abnormalities correctable in the animal model do not
translate to humans. However, the trials performed to
date do not provide definitive answers, as lack of efficacy
could also result from a variety of factors affecting the
outcome of the studies. As discussed above, these include
inadequate trial design for translation of results from ani-
mal models to man, insensitive outcome measures, a need
to measure outcomes across the spectrum of core and asso-
ciated phenotypes rather than a single behavior, need to test
the targeted treatments in younger patients with FXS due
to the developmental nature of the condition and lack of
clarity about the duration of plasticity windows, need for
optimizing individual dosage and longer exposure times to
see change in a developmental condition, and need to sort
out response variability with biomarkers both to identify
potential responders and to establish target engagement.
Further, effect sizes in the child study for numerous
measures in the high dose group are comparable to those
of marketed psychotropic drugs and for phenotype rever-
sal in animal models. These results suggest that lack of
statistical significance is due to enrollment of a cohort size
that was underpowered for significance. In comparison,
definitive trials for registration of commonly used antide-
pressants in adults typically enrolled between 300 and
1100 subjects [31] to achieve statistical significance for an
effect size of 0.31. A meta-analysis of all published anti-
depressant trials performed in children and adolescents
(n = 3000) identified comparable or slightly smaller effect
sizes in children and adolescents [43]. Statistical signifi-
cance is achieved in these trials by enrolling larger cohorts
than are practical for rare disorders such as FXS. We
suggest that clinicians consider effect size, number needed
to treat, or success rate differences [44], in addition to
p values, when assessing benefit of novel therapeutics.
Furthermore, we suggest that multi-component outcome
analyses at the group and subject level, using strategies
such as permutation testing [45], are likely to better index
the overall effect size in rare genetic disorders by taking
into account the entire condition and may be a helpful
strategy for assessing efficacy in smaller cohorts.
A larger study designed to address all the above issues
will be required to assess whether or not the etiologic
model is wrong. Indeed, a flexible dose trial enrolling
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larger cohorts of children titrated to the optimal dose of
drug or placebo, employing a multi-component primary
outcome that evaluates FXS-related problems across
behavioral, social, and language phenotypes and also
incorporates parenting stress and quality of life, would
represent a more thorough evaluation of arbaclofen
efficacy in FXS. In a genetically defined developmental
condition with variable impairment across multiple cogni-
tive and behavioral domains, it is likely that key outcome
definitions will need to address the entire condition rather
than one behavior, for successful translation to humans of
targeted treatments that correct synaptic phenotypes in
animal models.
Conclusions
FXS has been a model neurodevelopmental disorder for
clinical trials directed at translating to humans the treat-
ments that correct core pathophysiological mechanisms
in animal models. It seems clear from the trials reported
here and in other trials reported to date [46] that such
translation to humans is challenging and that it will be
important to learn from these early attempts to improve
methodology and the drug development process. Despite
failing to document significant improvement on the pro-
spectively defined primary endpoints, arbaclofen appears
to provide therapeutic benefit in some individuals with
FXS. These encouraging results suggest arbaclofen should
be studied further to replicate the result. Young age, higher
doses, larger cohort sizes, trial designs that minimize
placebo effect, and better outcome measures covering a
wide range of potential responses are among the factors
that may allow success in future trials of arbaclofen and
other drugs that have shown promise in FXS experi-
mental models.
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